参考文献
参考文献
[1] 类风湿关节炎诊断及治疗指南[J]. 中华风湿病学杂志,2010(04):265270.
[2] Josef S Smolen,Robert Landewé,Ferdinand C Breedveld,et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs[J]. Annals of the Rheumatic Diseases,2010,69(6):964-975.
[3] Smolen J S,Aletaha D,Bijlsma J W J,et al. Treating rheumatoid arthritis to target: recommendations of an international task force[J]. Ann Rheum Dis,2010, 69(4):631-637.
[4] Firestein G S,Zvaifler N J. How important are T cells in chronic rheumatoid synovitis?: II. T cell-independent mechanisms from beginning to end.[J]. Arthritis and rheumatism,2002,46(2):298.
[5] Nepom G T,Byers P,Seyfried C,et al. HLA genes associated with rheumatoid arthritis. Identification of susceptibility alleles using specific oligonucleotide probes.[J]. Arthritis and rheumatism,1989,32(1):15.
[6] Weyand C M,Hicok K C,Conn D L,et al. The influence of HLA-DRB1 genes on disease severity in rheumatoid arthritis.[J]. Annals of internal medicine, 1992,117(10):801.
[7] Boki K A,Drosos A A,Tzioufas A G,et al. Examination of HLA-DR4 as a severity marker for rheumatoid arthritis in Greek patients.[J]. Annals of the Rheumatic Diseases,1993,52(7):517.
[8] Hameed K,Bowman S,Kondeatis E,et al. The association of HLA-DRB genes and the shared epitope with rheumatoid arthritis in Pakistan.[J]. British journal of rheumatology,1997,36(11):1184-1188.
[9] Calin A,Elswood J,Klouda P T. Destructive arthritis, rheumatoid factor, and HLA-DR4. Susceptibility versus severity, a case-control study.[J]. Arthritis and rheumatism,1989,32(10):1221.
[10] Kirschmann D A,Duffin K L,Smith C E,et al. Naturally processed peptides from rheumatoid arthritis associated and non-associated HLA-DR alleles. [J]. Journal of Immunology,1995,155(12):5655-5662.
[11] Annette H M van der Helm-van Mil,Verpoort K N,Breedveld F C,et al. The HLA-DRB1 shared epitope alleles are primarily a risk factor for anti-cyclic citrullinated peptide antibodies and are not an independent risk factor for development of rheumatoid arthritis.[J]. Arthritis & Rheumatism,2010,54(4):1117-1121.
[12] Jawaheer D,Li W,Graham R R,et al. Dissecting the Genetic Complexity of the Association between Human Leukocyte Antigens and Rheumatoid Arthritis[J]. American Journal of Human Genetics,2002,71(3):585-594.
[13] Kang C P. The influence of a polymorphism at position -857 of the tumour necrosis factor alpha gene on clinical response to etanercept therapy in rheumatoid arthritis.[J]. Rheumatology,2005(4):547-552.
[14] Rodríguez M R,Núñez Roldán A,Aguilar F,et al. Association of the CTLA4 3′ untranslated region polymorphism with the susceptibility to rheumatoid arthritis[J]. Human Immunology, 2002,63(1):76-81.
[15] Yamamoto K,Suzuki A,Chang X,et al. Functional haplotypes of PADI4,encoding citrullinating enzyme peptidylarginine deiminase 4,are associated with rheumatoid arthritis[J].Nature Genetics,2003,34(4):395-402.
[16] Barton A,Bowes J,Eyre S S,et al. A functional haplotype of the PADI4 gene associated with rheumatoid arthritis in a Japanese population is not associated in a United Kingdom population[J]. Arthritis & Rheumatology,2014,50(4):11171121.
[17] Begovich A B,Carlton V E H,Honigberg L A,et al. A missense singlenucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis.[J]. American Journal of Human Genetics, 2004,75(2):330-337.
[18] Lang T J.Estrogen as an immunomodulator.[J].Clinical immunology: The official journal of the Clinical Immunology Society,2004,113(3):224-230.
[19] Yan Z,Lambert N C,Ostensen M,et al. Prospective study of fetal DNA in serum and disease activity during pregnancy in women with inflammatory arthritis[J]. Arthritis & Rheumatism, 2010,54(7):2069-2073.
[20] Nelson J L,Hughes K A,Smith A G,et al. Maternal-fetal disparity in HLA class II alloantigens and the pregnancy-induced amelioration of rheumatoid arthritis.[J]. N Engl J Med,1993,329(7):466-471.
[21] Brennan P,Barrett J, Fiddler M,et al. Maternal-fetal HLA incompatibility and the course of inflammatory arthritis during pregnancy.[J]. Journal of Rheumatology,2000, 27(12):2843-2848.
[22] Linn-Rasker S P, A H M van der Helm-van Mil, Gaalen F A V,et al. Smoking is a risk factor for anti-CCP antibodies only in rheumatoid arthritis patients who carry HLA-DRB1 shared epitope alleles.[J]. Annals of the Rheumatic Diseases, 2006,65(3):366.
[23] Doran M F,Pond G R,Crowson C S, et al. Trends in incidence and mortality in rheumatoid arthritis in Rochester,Minnesota,over a forty-year period. [J]. Arthritis & Rheumatism, 2010,46(3):625-631.
[24] Wong J B,Ramey D R,Singh G . Long-term morbidity,mortality, and economics of rheumatoid arthritis.[J]. Arthritis & Rheumatology,2001, 44(12):2746-2749.(https://www.daowen.com)
[25] Aken V J. Comparison of long term outcome of patients with rheumatoid arthritis presenting with undifferentiated arthritis or with rheumatoid arthritis: an observational cohort study.[J]. Annals of the Rheumatic Diseases,2006,65(1):20-25.
[26] van der Helm-van Mil A H,Verpoort K N,le Cessie S, et al. The HLADRB1 shared epitope alleles differ in the interaction with smoking and predisposition to antibodies to cyclic citrullinated peptide.[J]. Arthritis Rheum 2007,56(2):425432.
[27] Nell V P, Machold K P, Stamm T A, et al.Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis.[J]. Ann Rheum Dis 2005, 64(12):1731-1736.
[28] Maldonado I,Eid H,Rodriguez G R,et al. Rheumatoid nodulosis: is it a different subset of rheumatoid arthritis?.[J]. Journal of Clinical Rheumatology Practical Reports on Rheumatic & Musculoskeletal Diseases,2003,9(5):296-305.
[29] Allantaz F,Punaro M,Pascual V,et al.Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade.[J].The Journal of Experimental Medicine,2005,201(9):1479-1486.
[30] Jacobsson L T, Turesson C, Nilsson J A, et al.Treatment with TNFblockers and mortality risk in patients with rheumatoid arthritis.[J]. Ann Rheum Dis, 2007,66(5):670-675.
[31] Genovese M C, Bathon J M, Martin R W, et al.Etanercept versus methotrexate in patients with early rheumatoid arthritis: Two-year radiographic and clinical outcomes.[J].Arthritis Rheum,2002,46(6):1443-1450.
[32] Lipsky P E,Heijde D M V D,Clair E W S,et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group[J]. New England Journal of Medicine,2000, 343(22):1594-1602.
[33] Kremer,Joel M. Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized,doubleblind, placebo-controlled trial.[J]. Annals of Internal Medicine,2002,137(9):726733.
[34] Clair E W S,Heijde D M V D,Smolen J S,et al.Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: A randomized, controlled trial.[J].Arthritis Rheum,2004,50(11):3432-3443.
[35] O’Dell J R,Elliott J R,Mallek J A,et al. Treatment of early seropositive rheumatoid arthritis: doxycycline plus methotrexate versus methotrexate alone.[J]. Arthritis & Rheumatism, 2014,54(2):621-627.
[36] Lehman A J,Esdaile J M,Klinkhoff A V,et al. A 48-week, randomized,double-blind, double-observer,placebo-controlled multicenter trial of combination methotrexate and intramuscular gold therapy in rheumatoid arthritis: results of the METGO study.[J]. Arthritis & Rheumatism,2014,52(5):1360-1370.
[37] Cohen S B,Emery P,Greenwald M W,et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized,double-blind, placebo-controlled,phase III trial evaluating primary efficacy and safety at twenty-four weeks.[J]. Arthritis & Rheumatism,2006, 54(9):2793-2806.
[38] Aletaha D,Smolen J .The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis.[J]. Clinical & Experimental Rheumatology,2005,23(5 Suppl 39):S100-S108.
[39] Puolakka K,Kautiainen H,Timo Möttönen,et al. Early suppression of disease activity is essential for maintenance of work capacity in patients with recentonset rheumatoid arthritis: five-year experience from the FIN-RACo trial.[J].Arthritis& Rheumatology,2014, 52(1):36-41.
[40] Quinn M A,Conaghan P G,O’Connor P J,et al. Very early treatment with infliximab in addition to methotrexate in early,poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: Results from a twelve-month randomized, double-blind, placebo-controlled trial[J]. Arthritis & Rheumatism, 2005,52(1):27-35.
[41] Smolen J S,Heijde D M V D,St Clair E W, et al.Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial.[J]. Arthritis and rheumatism,2006,54(3):702-710.
[42] Turesson C,Jacobsson L T,Sturfelt G,et al. Rheumatoid factor and antibodies to cyclic citrullinated peptides are associated with severe extra-articular manifestations in rheumatoid arthritis.[J].Ann Rheum Dis,2007,66(1):59-64.
[43] Dohn U M,Ejbjerg B J,Court-Payen M,et al.Are bone erosions detected by magnetic resonance imaging and ultrasonography true erosions? A comparison with computed tomography in rheumatoid arthritis .[J]. Arthritis Research & Therapy, 2006,8(4):R110.
[44] 邹和建,邹耀红.类风湿关节炎与痛风[M].上海:上海科技教育出版社,2003:65-67.
[45] 涂汉军,罗杰.大众就医宝典[M].武汉:湖北科学技术出版社, 2010:16.
[46] 田捷,董瑞雪.轻松搞定风湿病[M].长春:吉林科学技术出版社, 2004: 40-41.
[47] 娄玉钤,李俊德.中医教您防治类风湿关节炎[M].北京:人民军医出版社,2015:193-194.
[48] 郭强. 类风湿关节炎病人就医指南[J]. 大众医学, 2013, 000(009):31-32.
[49] 徐汉军,罗杰.大众就医宝典[M].武汉:湖北科学技术出版社, 2010:3-24.